Specialty· August 10, 2026 · 19 min read
Topic
Dermatomyositis
Rare autoimmune myopathy access, VALOR Phase 3 brepocitinib evidence, Octagam IVIG coverage, and generic DMARD step therapy.
Rare autoimmune myopathy access, VALOR Phase 3 brepocitinib evidence, Octagam IVIG coverage, and generic DMARD step therapy.